The Neurology hub Laboratory (NeuroHubLab) is the research laboratory of the Neurology Service of the Bellvitge University Hospital, and it is integrated within the Neurological Diseases and Neurogenetic Group from the Bellvitge University Hospital and the Bellvitge Biomedical Research Institute (IDIBELL). We are a basic and translational laboratory focused on cutting-edge research, aimed at understanding, diagnosing, and finding effective treatments for various neurological disorders that affect the brain, spinal cord, and nervous system.

At our laboratory, we bring together a team of skilled neuroscientists, clinicians, bioinformaticians, and technicians who work collaboratively to unravel the complexities of neurologic diseases. Our mission is to advance the frontiers of neuroscience, improve patient care, and ultimately make a positive impact on the lives of those affected by these conditions.

Bellvitge Biomedical Research Institute (IDIBELL)
NeuroHubLab 1
NeuroHubLab 1
NeuroHubLab 1
NeuroHubLab 2
Bellvitge University Hospital (HUB)
previous arrow
next arrow

Recent news

Recent publications


Dec 12, 2023 by NeuroHubLab

Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort

This proof-of-concept study comparing benign and aggressive RRMS groups reinforces the potential role of baseline NfL serum levels as a promising long-term disability prognostic marker. In contrast, serum GFAP, total tau, and CHI3L1 levels demonstrated a lower or no ability to differentiate between the long-term outcomes of RRMS.

Aging NY

Aug 4, 2023 by NeuroHubLab

Proteostatic modulation in brain aging without associated Alzheimer’s disease-and age-related neuropathological changes

(Phospho)proteomics of old-aged subjects without cognitive or behavioral symptoms, and without AD-neuropathological changes and lacking any other neurodegenerative alteration will increase understanding about the physiological state of human brain aging without associate neurological deficits and neuropathological lesions.


March 31, 2023 by NeuroHubLab

Deregulated Transcription and Proteostasis in Adult mapt Knockout Mouse

Transcriptomics and phosphoproteomics were carried out in the cerebral cortex of B6.Cg-Mapttm1(EGFP)Klt (tau knockout: tau-KO) and wild-type (WT) 12 month-old mice to learn about the effects of tau ablation. Compared with WT mice, tau-KO mice displayed reduced anxiety-like behavior and lower fear expression


Jan 12, 2023 by NeuroHubLab

Natalizumab continuation versus switching to ocrelizumab after PML
risk stratification in RRMS patients: a natural experiment

Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing–remitting multiple sclerosis (RRMS). In patients treated with NTZ, screening for JC virus (JCV) is mandatory, and a positive serology usually requires a change in treatment after 2 years. In this study, JCV serology was used as a natural vexperiment to pseudo-randomize patients into NTZ continuation or OCR.

Voice ALS

Dec 12, 2022 by NeuroHubLab

Voiceprint and machine learning models for early detection of bulbar dysfunction in ALS

Bulbar dysfunction is a term used in amyotrophic lateral sclerosis (ALS). It refers to motor neuron disability in the corticobulbar area of the brainstem which leads to a dysfunction of speech and swallowing. One of the earliest symptoms of bulbar dysfunction is voice deterioration char- acterized by grossly defective articulation, extremely slow laborious speech, marked hypernasality and severe harshness.

previous arrowprevious arrow
next arrownext arrow


Funciona gracias a WordPress